Follow
A pharmaceutical company is bound to provide a new EpiPen alternative for free.
STATES CHRONICLE – After only one week since the EpiPen alternative was introduced on the market by CVS for $10, another competitor is bound to launch a similar product which will be free for everyone who needs it. Auvi-Q is a system which uses an injection filled with adrenaline, the product being similar to EpiPen. Kaleo Pharma, the manufacturer, stated that the product was recalled last year and starting on February 14 it will return to the market.
The price will reach $360. Nevertheless, there will be two separate methods through which people can get the treatment for free. Individuals who have health insurance will be able to acquire Auvi-Q for free. What is more, people who live in households with annual income lower than $100,000 will also be provided the new treatment for no costs.
Taking into consideration the fact that almost all Americans have health insurance and those who don’t have it are very likely to be part of the disadvantaged group, it seems that the new treatment will be available for nearly everyone. Spencer Williamson, the CEO, and president of Kaleo has stated on January 19 that there is no other EpiPen alternative which implies no costs except their product.
The release of the treatment known as Auvi-Q appears after several months of non-productive publicity for Mylan, the developer of EpiPen. This company has been so long debated since its launch last summer for asking customers $600 and additional retail prices for their revolutionary product. This is an adrenaline system based on an auto-injection developed to ward off anaphylactic shocks during a severe allergy attack.
After the pharmaceutical company Mylan has been criticized by politicians, consumer watchdogs and parents for raising its prices by 500% over a decade, the EpiPen maker decided to offer more rewarding coupons while they had also introduced a generic EpiPen in recent months. Nevertheless, experts believe that Mylan is on the verge of losing its near-supremacy regarding the market of allergy prescription.
This may happen because a full range of alternatives has been launched, undercutting the pharmaceutical company on pricing. CVS Health has recently claimed that it will sell a generic version of an EpiPen alternative named Adrenaclick which was estimated to cost $110 per pack made of two injections.
Image source: flickr
